Edition:
United States

Key Developments: Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.94AUD
30 May 2016
Change (% chg)

-- (--)
Prev Close
$1.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
931,410
52-wk High
$4.16
52-wk Low
$1.14

Latest Key Developments (Source: Significant Developments)

Mesoblast Ltd announces improved outcomes using Mesoblast cells in end stage heart failure
Tuesday, 24 Jun 2014 09:19pm EDT 

Mesoblast Ltd:Says that trial results evaluating a low dose of Mesoblast's proprietary mesenchymal precursor cells (MPCs) in patients with end-stage or class IV New York Heart Association (NYHA) heart failure who receive a left ventricular assist device.The multi-center, randomized, placebo-controlled trial compared outcomes in 30 end-stage or NYHA class IV heart failure patients requiring LVAD mechanical support who received either a single low dose injection into damaged heart muscle of allogeneic, or off-the-shelf, MPCs or a placebo injection.The trial investigators concluded that administration of a low MPC dose appeared to be safe and there was a potential signal of efficacy.The trial results showed that a single low dose MPC injection was associated with increased ability to maintain circulation without LVAD support, reduced early mortality, and reduced rehospitalization rates compared with control injections.  Full Article